Clinical Effects of Lithospermum Ruderale Dosage and Using-time on Medicinal Abortion Induced by Mifepristone and Misoprostol

The clinical effects of dosage during the period of treatment of Lithospermum Ruderale extract-a kind of Chinese traditional herbal medicine-on medicinal abortion induced by mifepristone and misoprostol were studied. Lithospermum Ruderale extract was administrated 3 d before, 3 d after or 3 d before plus 3 d after the administration of misoprostol respectively. The dose of Lithospermum Ruderale extract was 50 g, 75 g or 100 g respectively. Thus 1 350 women of early pregnancy were grouped into 9 groups and observed. The results showed that the effects of Lithospermum Ruderale used 3 d before, and 3 d before plus 3 d after (6 days misoprostol were significantly better than those only used 3 d after misoprostol both for complete abortion and bleeding (P<0.05). The dosage between 50 g and 100 g made no significant difference in clinical effects. Therefore it is reasonable to use 50 g Lithospermum Ruderale before misoprostol to improve medicinal abortion.

Clinical Effects of Lithospermum Ruderal on Medical Abortion by Mifepristone with Misoprostol

Early pregnancies(<42d)in 600 women were terminated respectively by mifepristone and Lithospermum Ruderal with misoprostol or mifepristone with misoprostol. The results showed that the rate of complete abortion(99.00%)of 300 women by mifepristone and Lithospermum Ruderal with misoprostol was significantly higher than that (92. 33%)of the other 300 women by mifepristone with misoprostol(P<0.01).The average length of time of embryo removal(54.01±7.55 h)and the rate of embryo removal (82.33%)within 6 hours after administration of misoprostol of the former were significantly shorter and higher than those(56.41±9.93 h and 72.67%) of the latter(P<0.05 respectively).The average length of the bleeding time of the former(7.01±3.11d)was significantly shorter than that(8.09±5.63d)of the latter(P<0.05).The recovery of the menstruation of both was not significantly different from each other(P>0.05).In all, the medical abortion by mifepristone and Lithospermum Ruderal with misoprostol was even more successful,with less bleeding time.Therefore it is essential to make researches on the auxiliary effects of Lithospermum Ruderal on the medical abortion by mifepristone with misoprostol.

Studies on Expression of IGF-II Gene in Deciduas Derived from Medical Abortion Patients

To determine the effect of insulin like growth factor Ⅱ(IGF Ⅱ) upon the maintenance of decidua in early pregnancy and its relationship with progesterone, as well as its role in medical abortion. Materials & Methods Decidua tissue was obtained from 28 women who undergoing surgical abortion and 39 for medical abortion respectively at 5~7 weeks of gestation. The extracted total RNA was reversely transcripted and amplified by PCR with specific primers (IGF Ⅱ and β actin). The products were semi quantitated by MIAS 300 system and qualitatively analyzed by southern blotting. Results The expression of IGF Ⅱ gene in decidua from surgical abortion was significantly higher than that from medical abortion (P<0.05). The average IGF Ⅱ gene transcription values were 1.54±0.79 and 0.72±0.39 respectively. The results of southern blotting proved qualitatively that the RT PCR products were IGF Ⅱ cDNA. Conclusion IGF Ⅱ plays a role in the maintenance of decidua in early pregnancy. It may act as a mediator of progestin. It's also involved in the molecular mechanism of mifepristone.

Effect of Mifepristone on the Telomerase Activity in Chorion and Decidua during Early Pregnancy

Objective To investigate telomerase activity in chorion and decidua from abortion induced by mifepristone incorporated with misoprostol at early pregnancy. Methods TRAP-SYBR Green assay was used to detect the expression of telomerase. Forty specimen were obtained from medicinal abortion （experiment group） and forty were from normal induced abortion （control group）. Results Positive expression of chorion telomerase was significantly different between the experimental group （28%, 11/40） and the control group （73%, 29/40） （P〈0.05）. While in decidua, the positive rate was 28% （11/40） in the experimental group and 20% （9/40） in the control group, there was no significant difference （P〉0.05）. Conclusion It is suggested that miferistone may significantly decrease the telomerase activity in chorion but not in decidua.

Clinical Observation on Termination of Early Pregnancy of 213 Cases after Caesarian Section with Repeated Use of Mifepristone and Misoprostol

Objective To investigate the efficacy and safety in women after caesarian section for termination of early pregnancies by treatment, or repeated treatment with mifepristone and misoprostol. Subjects and Methods A total of 213 pregnant women with amenorrhea of 34~69 d after caesarian section who asked for medical abortion were recruited, including 63 cases undergoing their second medical abortion. A total amount of mifeprisstone of 150 mg given in separate doses (25 mg×4 and 50 mg at the first time) was administered orally within 3 d, followed by misoprostol of 0.6 mg orally in the morning of d 3. Results The complete abortion rate was 92.5%, incomplete abortion was 4.7% and failure was 2.8%. Conclusion The sequential use of mifepristone and misoprostol could be successfully and repeatedly used for induced abortion in those women with a caesarian section history. Its efficacy was similar to that for ordinary population. Its safety and effectiveness were satisfactory.

Safety of Mifepristone in Medical Abortion in Hyperthyroidism Pregnant Mice

Objective:To study the safety of mifepristone on thyroid hormone level by using hyperthyroidism pregnant model in mouse to simulate the process of medical abortion and observe the changes of thyroid hormone during abortion.Methods:A total of 60 female Institute of Cancer Research(ICR)mice aged 6-8 weeks were divided into control group,control group with 0 mgRU486 group(control-0 mgRU486),control group with 2 mgRU486 group(control-2 mgRU486),hyperthyroid pregnant mice with 0 mgRU486 group(hyper-0 mgRU486),hyperthyroid pregnant mice with 2 mgRU486 group(hyper-2 mgRU486),and hyperthyroid pregnant mice with 20 mgRU486 group(hyper-20 mgRU486).In the hyperthyroidism groups,L-thyroxine sodium was intraperitoneally injected every day at 30μg·kg^(−1)·day^(−1) until the end of the experiment.On the 7^(th) day of the experiment,free triiodothyronine(FT3),free tetraiodothyroxine(FT4),thyroxine(TT4),and thyroid-stimulating hormone(TSH)levels were tested.The mice in the control groups and those in the experimental groups were paired with the male mice(2:1)on the 10^(th) day of the experiment,and the caging was recorded.On the 8^(th) day of pregnancy(day 8),pregnant mice were subcutaneously injected with mifepristone in different doses and were sacrificed 6 h later.Pregnancy rate and the number of embryos were recorded.Thyroid tissues were observed by hematoxylin and eosin(HE)staining.Serum TSH level was determined by radioimmunoassay.Results:Six hours after injection with mifepristone,serum FT3,FT4,and TT4 levels of pregnant mice were all increased.The increased levels in the mice under hyperthyroidism were different from those in the control groups(P<0.05).There was no difference in the embryo number and pregnancy rate between the experimental and the control groups;HE staining indicated that there was no significant change in microscopic features before and after mifepristone administration.Conclusion:Serum thyroid hormone level of mice under hyperthyroidism was significantly increased after mifepristone administration.Therefore,mifepristone should be avoided when hyperthyroidism has not been controlled.

Studies on Relationship between Serum Nitric Oxide and Plasma Cyclic Guanosine Monophosphate and Prolonged Bleeding after Medical Abortion as well as Prophylaxis and Treatment of Bleeding with Traditional Chinese Medicine

Objectives To study the relationship between serum nitric oxide (NO and plasma cyclic guanosine monophosphate (cGMP) and prolonged bleeding after medical abortion. Methods A total of 120 women having received medical abortions at random were recruited and divided into two groups: the one (Group A,n=60) taking 'Gong Fu Mixture(Uterus Recovering Mixture)' and the other (Group B,n=60) not taking it after abortion. On d 10, 20 and 30 after medical abortion, serum NO and plasma cGMP were tested before and after mifepristone administration and 10 d later by Gresis reaction method and radioimmunoassay respectively. Results NO concentration in serum and cGMP concentration in plasma decreased significantly after taking mifepristone given (P<0.05). Ten days later, the number of those with bleeding discontinuation in the group A was significantly greater than that in the group B (P<0.05). Serum NO level and plasma cGMP level in the group A decreased more significantly than those in the group B (P<0.05). Conclusion The slow decrease of serum NO and plasma cGMP is closely related to prolonged bleeding after medical abortion. “Gong Fu Mixture (uterus recovering mixture)” is effective in prevention and treatment of prolonged bleeding.

Efficacy of Single Dose of Mifepristone Combined with Two Doses of Misoprostol in Early Medical Abortions

Objective To study the efficacy of single dose of mifepristone and two doses of misoprostol in women undergoing early medical abortion （EMA） up to 9 weeks of gestation. Methods An audit was performed on a retrospective data analysis of 162 women who underwent an early medical abortion in Southampton U.K. Relevant data on completeness of abortion and other details were analyzed. Results Majority of the women （67%） aged 20-30 years old, 22% were between 30 and 40 years old and 1% were above 40 years old when they came for abortion. About 94.5% women had complete abortion following the use of single dose mifepristone combined with two doses of misoprostol, 4.9% had an incomplete abortion and 0.6% had failure of the procedure. These figures had significantly improved over the results of similar audit in 2005 with single dose of misoprostol to women below 7 weeks of pregnancy. The results in this audit were 82.1% complete abortion, 7.2% incomplete abortion and O. 7% failed procedure. Conclusion Mifepristone in combination with two doses of misoprostol appears to be more effective in all cases of early medical abortion when compared with single dose of misoprostol for termination below 49 d （7 weeks） and two doses of misoprostol between 49 d and 63 d （7-9 weeks） of pregnancy.

A prospective randomized, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy

A prospective randomized, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Author: Dr Roopa Malik, Assistant Professor, Obstetrics and gynaecology department Pt BDS PGIMS Rohtak BACKGROUND: Vaginal misoprostol has been shown to be an effective single agent for medical agent for medical abortion. This randomized, placebo controlled trial compared a regimen of mefipristone and misoprostol with misoprostol alone for termination of early pregnancy. METHODS: 200 women with gestation <56 days were randomized by a random number table to receive either 200 mg mifepristone orally or placebo followed 48 h later by 800 ug vaginal misoprostol. Abortion success was defined as complete abortion without the use of surgical aspiration. RESULTS: Successful medical abortions occurred in 96 out of 100 subjects (96%) after mifepristone followed by vaginal misoprostol. In all, 79 out of 100 subjects (79%) successfully aborted after placebo and vaginal misoprostol. The higher success rate of complete abortion with mifepristone and misoprostol regimen was statistically significant compared with the placebo and misoprostol regimen (p < 0.05). CONCLUSION: A regimen of mifepristone and misoprostol was significantly more effective for termination of pregnancies <56 days than misoprostol alone. The misoprostol alone regimen for termination of early pregnancy is not a very good method for medical abortion but 79% efficacy obtained with vaginal misoprostol alone may clinically acceptable when mifepristone is not available.

Clinical Study on the Termination of 388 High-risk Early Pregnancies with Mifepristone and Misoprostol

To inverstgate the safety, effectiveness and acceptability Of conbination Of mifepristone and misoproslol for termination of high-risk pregnancy (amenorrhea≤ 70 days ).Three hundred and eighty-eight high-risk pregnant women, complicated with scarreduterus, or reproductive tract malformation, or uterus fibromyoma, or histories of recentabortion or repeated abortions, or pregnancy during lactation, and having duration of gestation ranging from 34 to 69 days, were administered orally 150 mg mifepristone (50 mgat the first time, and then 25 mg q 12 h × 4), and 600 μg misoprostol on the third day.The complete abortion rate ωas 92. 3%, while the incomplete abortion rate was 6. 2%, ongoing and pregnancy rate was 1. 5%. It was shown that combination of mifepristone andmisoprostol was effective in inducing abortion Of those high-risk pregnancies. Theregimen's effectiveness for high-risk population was similar to that for general population. Its safety, effectiveness and acceptability were satifactory. In addition, the softenedand dilated cervix made it easier and less painful to make vacuum aspiration in case offailure of the abortion.

Role of cyclooxygenase-2 signaling pathway dysfunction in unexplained recurrent spontaneous abortion

Background Experimental evidence indicates that cyclooxygenase-2 （COX-2） plays a critical role in blastocyst implantation; however, little is known of the role of COX-2 in unexplained recurrent spontaneous abortion （URSA）. Methods We evaluated the expression level and potential signaling pathway of COX-2 in 30 cases of URSA who were excluded the abnormality of chromosomes, anatomy, endocrine, infectious, autoimmune diseases and in 30 normal pregnancies. Results The mRNA and the protein expression level of COX-2 in the URSA group （-0.238±0.848, 0.368±0.089, respectively） were significantly lower than that in the control group （1.943±3.845, 1.046±0.108, respectively） （both, P 〈0.01）. The expression of prostaglandins PGF2a, PGD2, PGE2, and PGI2, in the URSA group （（2326.0±295.6） pg/ml, （2164.0±240.5） pg/ml, （238.7±26.4） pg/ml, （2337.0±263.0） pg/ml, respectively） were significantly lower than that in the control group （（3450.0±421.7） pg/ml, （3174.0±415.6） pg/ml, （323.5±43.8） pg/ml, （3623.0±460.4） pg/ml, respectively） （P 〈0.05）. The mRNA expression level of PPARI3 and RXRa （0.859±0.653, -0.172±0.752, respectively） in URSA group was significantly lower than that in the control group （1.554±1.735, 0.777±2.482, respectively） （both P 〈0.05）. The mRNA and protein expression levels of vascular endothelial growth factor-A （VEGF-A） in the URSA group （2.010±1.522, 0.35±0.46） was significantly lower than that in the control group （4.569±2.430, 0.750±0.350） （both P 〈0.05）. Conclusions COX-2 and the COX-2-derived PGI2 signaling pathway possibly play an important role in successful embryo implantation, and their decreased expression may result in URSA. The decreased expression may influence the expression of VEGF-A which interferes with placental angiogenesis causing failure of embryo implantation, leading to spontaneous abortion.

Comparison of Clinical Efficacy of Three Methods for Cervical Ripening followed by Surgical Evacuation in Early Missed Abortion

Objective To compare clinical efficacy of three cervical preparations for surgical evacuation in first trimester missed abortion. Methods Two hundred and ten women with early missed abortion were equally randomized into three groups. Three cervical preparations, Dilapan-dilator method （group A, n= 70）, mifepristone method （group B, n= 70）, and misoprostol method （group C, n= 70）, were used 24 h before curettage for terminating missed abortion, respectively. Clinical outcomes and complications for these three methods were compared. Results No differences were found in rates of successful treatment among the three groups （P〉O.05）. The incidence of fitting number 8 Hegar dilator was slightly high in group A, but it was not different compared with that in group B or group C （P〉0.05）. Bleeding in previous 24 h in group C was significantly greater than that in group A or group B （P〈0.01）. The cases of blood loss （〉50 ml） during evacuation in group B were more than those in group A （P〉0.05）. Women in group B had less abdominal pain than those in group A or group C （P〈0.01）. Side effects in group C were more than those in group A on nausea （P〈0.01）, vomiting （P〈0.05）, and diarrhea （P〈0.01）. Group B had the highest acceptability among the three groups （P〈0.05）. Conclusion Three methods have the similar clinical efficacies in cervical ripening for surgical treatment of early missed abortion. Based on individual characteristics, different approach would be chosen to avoid some adverse events and improve the clinical application of Dilapan-dilator.

Termination of Missed Abortion in A Combined Procedure: A Randomized Controlled Trial

Objective To access an ideal procedure terminating missed abortion within 12 weeks of gestational age. Methods Women with intrauterine fetal death were randomized into 3 groups. Group A （n=30）： vaginal misoprostol （MP） 0.4 mg, 3 h before vacuum aspiration; group B（n=15）： vaginal MP 0.4 mg every 3 h, up to 5 doses; group C（n=30）： oral mifepristone （MF） 200 mg 36-48 h before vaginal MP 0.4 mg, MP was given every 3 h, up to 5 doses. Results Women in group A had the shortest interval of gestation tissue expulsion （3.2± 0.5 h） and the bleeding （3.2 ± 5.7 ml） during medical procedure, which were statistically significant in comparison with the other two groups （P〈0.001, P〈0.01, respectively）. Success rates of groups A, B and C were 100%, 33.3% and 90.0%, respectively. Percentages of women need surgical interventions were similar in group B and group C（80.0%,76.7%, respectively）. Bleeding during operation, pain after medical procedure and satisfaction presented no statistical significance among the 3 groups. Conclusion Vaginal MP followed by vacuum aspiration was valuable in safety, and efficacy, which led to less bleeding and a faster recovery.

女性药物流产后加用米非司酮的治疗效果

目的探析女性采取药物流产后予以米非司酮药物治疗的效果。方法选取2020年4月至2021年4月河北省人民医院就诊的70例药物流产患者作为研究对象,根据随机数字表法分为对照组(35例)和观察组(35例)。两组均采用药物流产治疗,对照组不加用药物,观察组行米非司酮治疗,比较两组治疗效果及不良反应情况。结果观察组流产情况优于对照组,观察组阴道出血量低于对照组,出血持续时间短于对照组,观察组治疗后卵泡刺激素(FSH)、黄体生成素(LH)、孕酮(P)及雌二醇(E2)水平与不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论米非司酮药物应用在女性药物流产后效果显著,可提升患者完全流产率,缩短患者出血持续时间,有效减少患者流产后的阴道出血量,同时对患者激素水平进行调节,降低患者不良反应发生率,促进患者流产后的恢复,临床上可借鉴及推广。

桂枝茯苓胶囊联合米非司酮配伍米索前列醇治疗不全流产的效果

目的:评价桂枝茯苓胶囊联合米非司酮配伍米索前列醇治疗不全流产的效果。方法:选取2020年3月—2022年6月酒泉市人民医院收治的82例不全流产患者作为研究对象。根据随机数表法将其分为对照组和观察组,各41例。对照组给予米非司酮配伍米索前列醇治疗,观察组在对照组基础上给予桂枝茯苓胶囊。比较两组临床疗效,时间指标,治疗前、治疗后5 d子宫螺旋动脉血流指标,治疗前、治疗后14 d性激素。结果:观察组总有效率为92.68%,高于对照组的78.05%,差异有统计学意义(P<0.05)。观察组完全流产患者孕囊排出时间、阴道出血停止时间早于对照组,腹痛持续时间短于对照组,腹痛程度分级低于对照组,差异有统计学意义(P<0.05)。观察组治疗后5 d舒张末期流速(PDV)明显低于治疗前和对照组,阻力指数(RI)明显高于治疗前和对照组,差异有统计学意义(P<0.05)。两组治疗前、治疗后14 d血清雌二醇(E_(2))、孕酮(P)水平比较,差异无统计学意义(P>0.05);两组治疗后14 d血清E_(2)、P水平均明显高于治疗前,差异有统计学意义(P<0.05)。结论:桂枝茯苓胶囊联合米非司酮配伍米索前列醇治疗不全流产可缩短阴道流血时间,减轻腹痛程度,提高子宫螺旋动脉血流阻力和疗效。

3种流产剂对大鼠妊娠干预作用的比较研究

为研究米非司酮、溴隐亭和脂多糖3种流产剂对SD大鼠妊娠的影响。通过有无阴栓和阴道分泌物涂片确定SD大鼠是否妊娠,并将妊娠大鼠随机分为空白对照组、米非司酮组、溴隐亭组和脂多糖组。空白对照组于妊娠6~8 d皮下注射生理盐水,其余各组皮下注射相应流产剂,建立流产模型。于妊娠12 d观测各组流产率、血液生化指标,ELISA检测炎性细胞因子和孕激素水平,苏木精-伊红染色法(hematoxylin-eosin staining,HE)染色检测肝脏及子宫组织的病理学变化。结果显示,空白对照组、米非司酮组、溴隐亭组和脂多糖组的流产率分别为0、100%、50%和33.3%;与空白对照组相比,各流产剂致流产模型组大鼠子宫连胎重、孕激素水平均显著降低(P<0.05),TNF-α、IL-2、IL-12、IL-6、IL-1β水平均显著增加(P<0.05),且均会对肝、肾、子宫组织造成不同程度的代谢和病理性损伤;与空白对照组相比,各组核因子-κB(nuclear factor-kappa B,NF-κB)p65的表达更为强烈,雌激素受体(estrogen receptor,ER)表达水平降低。表明溴隐亭用于致流产的效果优于米非司酮和脂多糖,对母体损伤小。

孕早期增塑剂DEHP亚急性暴露影响蜕膜反应并增加流产风险

目的:探究邻苯二甲酸酯类增塑剂邻苯二甲酸二(2-乙基)己酯(DEHP)亚急性暴露对小鼠子宫内膜蜕膜反应和流产风险的影响。方法:分别选取300、1000、3000 mg·kg^(-1)·d^(-1)三个浓度梯度的DEHP对CD1小鼠进行经口亚急性暴露28 d。建立DEHP亚急性暴露小鼠早期自然妊娠模型和人工诱导假孕小鼠蜕膜反应模型,分别取自然妊娠第7天子宫组织和人工诱导蜕膜反应小鼠妊娠第8天诱导侧子宫组织,通过苏木精-伊红染色(HE染色)、Masson染色、TUNEL检测、蛋白质印迹法检测DEHP亚急性暴露对小鼠蜕膜反应的影响。构建300 mg·kg^(-1)·d^(-1) DEHP亚急性暴露小鼠自然流产模型,观察妊娠第10天的妊娠结局,探究蜕膜反应受损对小鼠妊娠的影响。结果:与空白对照组比较,DEHP大剂量组受孕率显著性降低(P<0.05);HE染色显示DEHP小剂量组和中剂量组蜕膜基质细胞排列杂乱、细胞核形态不规则、胞浆染色不均、多核细胞数显著降低;Masson染色显示DEHP小剂量组和中剂量组蜕膜组织的胶原纤维分布更多、数量增多、排列杂乱;TUNEL检测显示暴露组蜕膜组织细胞凋亡增加;蛋白质印迹法检测显示暴露组子宫内膜蜕膜反应标志分子BMP2蛋白表达水平显著降低(P<0.05或P<0.01);在米非司酮流产刺激下DEHP小剂量组小鼠流产率、胚胎吸收率显著升高,胚胎数、子宫湿重、子宫面积、胎盘湿重显著减少(P<0.05或P<0.01)。结论:DEHP亚急性暴露导致小鼠子宫内膜蜕膜反应受损加重小鼠妊娠流产风险。

米非司酮联合米索前列醇用于不同孕周药物流产效果

目的:探究米非司酮联合米索前列醇用于不同孕周药物流产效果。方法:选取2022年10月-2023年10月本院要求行药物流产者100例,根据妊娠孕周分为5~7周组(n=46)和8~12周组(n=54)。均给予米非司酮+米索前列醇药物干预,分析两组流产成功率、孕囊自然排出时间、阴道出血量、阴道出血时间、不良反应以及性激素水平变化。结果:5~7周组流产成功率(97.8%)高于8~12周组(83.3%),阴道出血量(71.1±8.1ml)和阴道流血时间(8.0±0.9d)均低于8~12周组(169.1±10.8ml、14.3±1.0d);流产后1周,两组孕酮水平均升高、雌二醇和卵泡刺激素水平均降低,且5~7周组改善效果优于8~12周组;5~7周组不良反应发生率(4.4%)低于8~12周组(18.5%)(均P<0.05)。结论:米非司酮联合米索前列醇药物流产对孕早期效果更优,可提高流产成功率,降低阴道出血量、出血时间和不良反应,改善性激素水平。

戊酸雌二醇联合米非司酮及米索前列醇治疗稽留流产的疗效

目的研究稽留流产治疗中应用戊酸雌二醇+米非司酮+米索前列醇的疗效。方法选取贵州省遵义市桐梓县中医医院妇科于2021年6月—2023年6月确诊为稽留流产的40例患者为研究对象,通过抽签方式将其分为比照组(20例,米非司酮+米索前列醇)与疗效组(20例,戊酸雌二醇+米非司酮+米索前列醇),比较两组清宫术开展情况、流产率、宫颈扩张情况、人工流产综合征发生情况。结果疗效组清宫术时间(5.84±0.16)min、术中出血量(60.13±2.35)mL,优于比照组清宫术时间(8.32±0.31)min、术中出血量(93.12±4.12)mL,差异有统计学意义(t=31.792、31.105,P均<0.05);疗效组完全流产率100.00%,优于比照组完全流产率80.00%,差异有统计学意义(χ^(2)=4.444,P<0.05);疗效组宫口开大程度(2.13±0.14)分、宫颈管消退程度(2.01±0.12)分,优于比照组宫口开大程度(1.40±0.16)分、宫颈管消退程度(1.65±0.21)分,差异有统计学意义(t=15.355、6.656,P均<0.05);疗效组人工流产综合征发生率为0,优于比照组的20.00%,差异有统计学意义(χ^(2)=4.444,P<0.05)。结论稽留流产治疗过程中应用戊酸雌二醇+米非司酮+米索前列醇可以提升宫颈扩张效果,有利于清宫术开展,提高流产成功率,降低人工流产风险。

米非司酮配伍米索前列醇治疗稽留流产的效果

目的探究米非司酮联合米索前列醇治疗稽留流产的效果。方法选择100例发生稽留流产的孕妇为研究对象,使用随机数字法将其分为对照组、研究组,每组50例。对照组采用100mg米非司酮顿服联合0.6mg米索前列醇治疗,研究组采用200mg米非司酮(分2d口服)联合0.6mg米索前列醇治疗。比较两组孕妇的人绒毛膜促性腺激素(HCG)水平恢复正常时间及稽留流产治疗成功率。结果研究组治疗成功率为84.00%,高于对照组的66.00%,差异有统计学意义(P<0.05)。研究组HCG水平恢复正常时间为(23.62±1.47)d,短于对照组的(25.03±1.54)d,差异有统计学意义(P<0.05)。结论分2d口服200mg米非司酮配伍米索前列醇治疗,能有效提高稽留流产治疗成功率,缩短HCG恢复时间。